Deutsche Bank
ORIC icon

Deutsche Bank’s Oric Pharmaceuticals ORIC Stock Holding History

Deutsche Bank’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$901K Sell
66,914
-6,964
-9% -$86.7K ﹤0.01% 2292
2026
Q2 		$800K Buy
73,878
+22,545
+44% +$204K ﹤0.01% 2503
2026
Q1 		$650K Buy
51,333
+6,396
+14% +$72.6K ﹤0.01% 2439
2025
Q4 		$368K Buy
44,937
+2,440
+6% +$28.1K ﹤0.01% 2720
2025
Q3 		$510K Buy
42,497
+3,920
+10% +$41.2K ﹤0.01% 2527
2025
Q2 		$392K Sell
38,577
-13,399
-26% -$90K ﹤0.01% 2578
2025
Q1 		$290K Sell
51,976
-5,461
-10% -$47.8K ﹤0.01% 2770
2024
Q4 		$464K Buy
57,437
+18,745
+48% +$172K ﹤0.01% 2647
2024
Q3 		$397K Buy
38,692
+9,331
+32% +$92.3K ﹤0.01% 2593
2024
Q2 		$208K Buy
29,361
+4,036
+16% +$36.1K ﹤0.01% 2780
2024
Q1 		$348K Buy
25,325
+549
+2% +$6.52K ﹤0.01% 2520
2023
Q4 		$228K Sell
24,776
-967
-4% -$6.99K ﹤0.01% 2793
2023
Q3 		$156K Buy
25,743
+3,808
+17% +$31.2K ﹤0.01% 2931
2023
Q2 		$170K Sell
21,935
-3,232
-13% -$18.4K ﹤0.01% 2983
2023
Q1 		$143K Hold
25,167
– – ﹤0.01% 3172
2022
Q4 		$148K Hold
25,167
– – ﹤0.01% 3123
2022
Q3 		$81K Sell
25,167
-10,103
-29% -$40.4K ﹤0.01% 3429
2022
Q2 		$158K Buy
35,270
+17,886
+103% +$71.4K ﹤0.01% 3298
2022
Q1 		$93K Sell
17,384
-2,038
-10% -$18.4K ﹤0.01% 3608
2021
Q4 		$285K Sell
19,422
-2,482
-11% -$38.7K ﹤0.01% 3180
2021
Q3 		$458K Buy
21,904
+1,692
+8% +$34.3K ﹤0.01% 3096
2021
Q2 		$358K Buy
20,212
+3,529
+21% +$77.3K ﹤0.01% 3446
2021
Q1 		$408K Buy
16,683
+137
+0.8% +$4.33K ﹤0.01% 3232
2020
Q4 		$560K Buy
16,546
+11,679
+240% +$335K ﹤0.01% 2831
2020
Q3 		$122K Buy
4,867
+422
+9% +$10K ﹤0.01% 3456
2020
Q2 		$150K Buy
+4,445
New +$142K ﹤0.01% 3264

Other funds holding ORIC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Zweig-DiMenna Associates
Zweig-DiMenna Associates New York $1.3B AUM 120.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Deutsche Bank's ORIC Position: Q3 2026 in Review

Deutsche Bank reduced its Oric Pharmaceuticals (ORIC) stake by 9.4% in Q3 2026, selling an estimated $86.7K and leaving 66,914 shares worth $901K. The position accounts for ﹤0.01% of the portfolio, ranked #2292.

Deutsche Bank first reported a position in ORIC in Q2 2020 and has held it in 26 quarters since. 48 funds tracked by Wall St. Rank hold ORIC as of Q3 2026.

  • Deutsche Bank held 66,914 shares of Oric Pharmaceuticals worth $901K as of Q3 2026.
  • Deutsche Bank sold 6,964 Oric Pharmaceuticals shares in Q3 2026, an estimated $86.7K.
  • Oric Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #2292 holding.
  • Deutsche Bank first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 26 quarters since.
  • 48 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.